126 related articles for article (PubMed ID: 26242994)
1. Role of the culture medium in porin expression and piperacillin-tazobactam susceptibility in Escherichia coli.
Pinet E; Franceschi C; Davin-Regli A; Zambardi G; Pagès JM
J Med Microbiol; 2015 Nov; 64(11):1305-1314. PubMed ID: 26242994
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the risk of acquiring in vitro resistance to doripenem and tazobactam/piperacillin by CTX-M-15-producing Escherichia coli.
Horiyama T; Kanazawa S; Hara T; Izawa M; Sato T; Yamaguchi T; Tsuji M; Maki H
J Infect Chemother; 2015 May; 21(5):381-4. PubMed ID: 25662788
[TBL] [Abstract][Full Text] [Related]
3. Antimicrobial susceptibility of well-characterised multiresistant CTX-M-producing Escherichia coli: failure of automated systems to detect resistance to piperacillin/tazobactam.
Pitout JD; Le P; Church DL; Gregson DB; Laupland KB
Int J Antimicrob Agents; 2008 Oct; 32(4):333-8. PubMed ID: 18701262
[TBL] [Abstract][Full Text] [Related]
4. Comparative assessment of inoculum effects on the antimicrobial activity of amoxycillin-clavulanate and piperacillin-tazobactam with extended-spectrum beta-lactamase-producing and extended-spectrum beta-lactamase-non-producing Escherichia coli isolates.
López-Cerero L; Picón E; Morillo C; Hernández JR; Docobo F; Pachón J; Rodríguez-Baño J; Pascual A
Clin Microbiol Infect; 2010 Feb; 16(2):132-6. PubMed ID: 19614715
[TBL] [Abstract][Full Text] [Related]
5. Exploring the effectiveness of tazobactam against ceftazidime resistant Escherichia coli: insights from the comparison between susceptibility testing and beta-lactamase inhibition.
Bethel CR; Hujer AM; Helfand MS; Bonomo RA
FEMS Microbiol Lett; 2004 May; 234(1):99-103. PubMed ID: 15109726
[TBL] [Abstract][Full Text] [Related]
6. Impact of tazobactam pharmacokinetics on the antimicrobial effect of piperacillin-tazobactam combinations.
Liu Q; Rand K; Derendorf H
Int J Antimicrob Agents; 2004 May; 23(5):494-7. PubMed ID: 15120729
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics-Pharmacodynamics of Tazobactam in Combination with Piperacillin in an In Vitro Infection Model.
Nicasio AM; VanScoy BD; Mendes RE; Castanheira M; Bulik CC; Okusanya OO; Bhavnani SM; Forrest A; Jones RN; Friedrich LV; Steenbergen JN; Ambrose PG
Antimicrob Agents Chemother; 2016 Apr; 60(4):2075-80. PubMed ID: 26787689
[TBL] [Abstract][Full Text] [Related]
8. Detection of Piperacillin-Tazobactam-Resistant/Pan-β-Lactam-Susceptible Escherichia coli with Current Automated Susceptibility Test Systems.
Monogue ML; Tanner LK; Brecher SM; Aslanzadeh J; Nicolau DP
Infect Control Hosp Epidemiol; 2017 Mar; 38(3):379-380. PubMed ID: 28069100
[No Abstract] [Full Text] [Related]
9. Proteomic analysis of Escherichia coli with experimentally induced resistance to piperacillin/tazobactam.
dos Santos KV; Diniz CG; Veloso Lde C; de Andrade HM; Giusta Mda S; Pires Sda F; Santos AV; Apolônio AC; de Carvalho MA; Farias Lde M
Res Microbiol; 2010 May; 161(4):268-75. PubMed ID: 20381611
[TBL] [Abstract][Full Text] [Related]
10. In the literature. Piperacillin-tazobactam and extended-spectrum β-lactamase--producing Escherichia coli.
Clin Infect Dis; 2013 Nov; 57(10):iii-iv. PubMed ID: 24308040
[No Abstract] [Full Text] [Related]
11. Pharmacodynamics of Ceftolozane plus Tazobactam Studied in an In Vitro Pharmacokinetic Model of Infection.
MacGowan AP; Noel AR; Tomaselli SG; Nicholls D; Bowker KE
Antimicrob Agents Chemother; 2016 Jan; 60(1):515-21. PubMed ID: 26552975
[TBL] [Abstract][Full Text] [Related]
12. In vitro efficiency of the piperacillin/tazobactam combination against inhibitor-resistant TEM- and complex mutant TEM-producing clinical strains of Escherichia coli.
Robin F; Krebs M; Delmas J; Gibold L; Mirande C; Bonnet R
J Antimicrob Chemother; 2011 May; 66(5):1052-6. PubMed ID: 21393211
[TBL] [Abstract][Full Text] [Related]
13. Risk factors for infection or colonization with CTX-M extended-spectrum-β-lactamase-positive Escherichia coli.
Han JH; Kasahara K; Edelstein PH; Bilker WB; Lautenbach E
Antimicrob Agents Chemother; 2012 Nov; 56(11):5575-80. PubMed ID: 22890772
[TBL] [Abstract][Full Text] [Related]
14. A piperacillin-tazobactam resistant Escherichia coli strain isolated from a faecal sample of a healthy volunteer.
London N; Thomson CJ; Amyes SG; Stobberingh E
FEMS Immunol Med Microbiol; 1995 Apr; 11(2):107-11. PubMed ID: 7640670
[TBL] [Abstract][Full Text] [Related]
15. Susceptibility of Escherichia coli isolates with TEM-1 beta-lactamase to combinations of BRL42715, tazobactam or clavulanate with piperacillin or amoxycillin .
Livermore DM; Seetulsingh P
J Antimicrob Chemother; 1991 Jun; 27(6):761-7. PubMed ID: 1669013
[TBL] [Abstract][Full Text] [Related]
16. Point mutations in the inc antisense RNA gene are associated with increased plasmid copy number, expression of blaCMY-2 and resistance to piperacillin/tazobactam in Escherichia coli.
Kurpiel PM; Hanson ND
J Antimicrob Chemother; 2012 Feb; 67(2):339-45. PubMed ID: 22117029
[TBL] [Abstract][Full Text] [Related]
17. An evaluation of the in vitro activity of piperacillin/tazobactam.
Daley D; Mulgrave L; Munro R; Neville S; Smith H; Dimech W
Pathology; 1996 May; 28(2):167-72. PubMed ID: 8743825
[TBL] [Abstract][Full Text] [Related]
18. Factors determining resistance to beta-lactam combined with beta-lactamase inhibitors in Escherichia coli.
Reguera JA; Baquero F; Pérez-Díaz JC; Martínez JL
J Antimicrob Chemother; 1991 May; 27(5):569-75. PubMed ID: 1653204
[TBL] [Abstract][Full Text] [Related]
19. Piperacillin tazobactam compared with co-amoxiclav, ampicillin plus sulbactam and timentin against beta-lactamase-producing clinical isolates of Escherichia coli, Klebsiella pneumoniae and Klebsiella oxytoca.
Traub WH; Leonhard B
Chemotherapy; 1995; 41(5):345-52. PubMed ID: 8521736
[TBL] [Abstract][Full Text] [Related]
20. Argentinean collaborative multicenter study on the in vitro comparative activity of piperacillin-tazobactam against selected bacterial isolates recovered from hospitalized patients.
Casellas JM; Tomé G; Bantar C; Bertolini P; Blázquez N; Borda N; Couto E; Cudmani N; Guerrera J; Juárez MJ; López T; Littvik A; Méndez E; Notario R; Ponce G; Quinteros M; Salamone F; Sparo M; Sutich E; Vaylet S; Wolff L
Diagn Microbiol Infect Dis; 2003 Nov; 47(3):527-37. PubMed ID: 14596972
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
